α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Rothhammer, Veit ^a   Muschaweckh, Andreas ^b   Gasteiger, Georg ^c   Petermann, Franziska ^a   Heink, Sylvia ^a   Busch, Dirk H ^b   Heikenwälder, Mathias ^b   Hemmer, Bernhard ^a,d   Drexler, Ingo ^e   Korn, Thomas ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d and Hygiene ^*  (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; FREUND ADJUVANT; HOMEODOMAIN PROTEIN; PERFORIN; PERFORIN 1, MOUSE; PORE FORMING CYTOTOXIC PROTEIN; RAG-1 PROTEIN; VERY LATE ACTIVATION ANTIGEN 4;

ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HELPER CELL; IMMUNOLOGY; MENINGOENCEPHALITIS; METABOLISM; MOUSE; PROCEDURES; RETROVIRUS INFECTION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIGENS, CD4; CELL DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; FREUND'S ADJUVANT; GENE EXPRESSION REGULATION, VIRAL; HOMEODOMAIN PROTEINS; INTEGRIN ALPHA4BETA1; MENINGOENCEPHALITIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PERFORIN; PORE FORMING CYTOTOXIC PROTEINS; RETROVIRIDAE INFECTIONS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84906564519     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-27     Document Type: Article

References (53)

1. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G: Functional and pathogenic differences of Th1 and th17 cells in experimental autoimmune encephalomyelitis. PLoS One 2010, 5: e15531. doi:10.1371/journal.pone.0015531 10.1371/journal.pone.0015531
2. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356: 63-66. doi:10.1038/356063a0 10.1038/356063a0
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899-910. doi:10.1056/NEJMoa044397 10.1056/NEJMoa044397
4. Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, Hemmer B, Korn T: Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011, 208: 2465-2476. doi:10.1084/jem.20110434 10.1084/jem.20110434
5. RansohoffRM, Engelhardt B: The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012, 12: 623-635. doi: 10.1038/nri3265 10.1038/nri3265
6. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN: Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011, 477: 216-219. doi:10.1038/nature10339 10.1038/nature10339
7. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D, Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349: 2004-2013. doi: 10.1056/NEJMoa030002 10.1056/NEJMoa030002
8. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362: 387-401. doi: 10.1056/NEJMoa0909494 10.1056/NEJMoa0909494
9. Selmaj K, Li DK, Hartung H-P, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E: Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013, 12: 756-767. doi:10.1016/S1474-4422(13)70102-9 10.1016/S1474-4422(13)70102-9
10. Miller DH, Weber T, Grove R, Wardell C, Horrigan J, GraffO, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X: Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012, 11: 131-139. doi:10.1016/S1474-4422(11)70299-X 10.1016/S1474-4422(11)70299-X
11. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F, Psoriasis Study Group: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2: 52ra72. doi:10.1126/scitranslmed.3001107
12. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366: 1190-1199. doi:10.1056/NEJMoa1109997 10.1056/NEJMoa1109997
13. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012, 71: 198-205. doi:10.1136/ard.2010.148700 10.1136/ard.2010.148700
14. Major EO: Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010, 61: 35-47. doi:10.1146/annurev.med.080708.082655 10.1146/annurev.med.080708.082655
15. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, Johnston RJ, Peters B, Rafii-El-Idrissi Benhnia M, Hoffmann J, Su H-P, Singh K, Garboczi DN, Head S, Grey H, Felgner PL, Crotty S: Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008, 28: 847-858. doi:10.1016/j.immuni.2008.04.018 10.1016/j.immuni.2008.04.018
16. Moutaftsi M, Bui H-H, Peters B, Sidney J, Salek-Ardakani S, OseroffC, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, Grey H, Sette A: Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol 2012, 178: 6814-6820.
17. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441: 235-238. doi:10.1038/nature04753 10.1038/nature04753
18. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK: Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13: 423-431. doi:10.1038/nm1564 10.1038/nm1564
19. Scott LM, Priestley GV, Papayannopoulou T: Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 2003, 23: 9349-9360. 10.1128/MCB.23.24.9349-9360.2003
20. Koedel U, Rupprecht T, Angele B, Heesemann J, Wagner H, Pfister H-W, Kirschning CJ: MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 2004, 127: 1437-1445. doi:10.1093/brain/awh171 10.1093/brain/awh171
21. Staib C, Drexler I, Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol 2004, 269: 77-100. doi:10.1385/1-59259-789-0:077
22. Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadán JG, Cush SS, Gibbs J, Molon B, Bronte V, Bennink JR, Yewdell JW: Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe 2013, 13: 155-168. doi:10.1016/j.chom.2013.01.004 10.1016/j.chom.2013.01.004
23. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK: Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006, 63: 1383-1387. doi:10.1001/archneur.63.10.1383 10.1001/archneur.63.10.1383
24. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B: Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76: 1214-1221. doi:10.1212/WNL.0b013e3182143564 10.1212/WNL.0b013e3182143564
25. Jelcic I, Aly L, Binder TMC, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann TH, Weber T, Girones R, Sospedra M, Martin R: T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 2013, 87: 3393-3408. doi:10.1128/JVI.02803-12 10.1128/JVI.02803-12
26. Eshima K, Chiba S, Suzuki H, Kokubo K, Kobayashi H, Iizuka M, Iwabuchi K, Shinohara N: Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol Lett 2012, 144: 7-15. doi:10.1016/j.imlet.2012.02.013 10.1016/j.imlet.2012.02.013
27. Jellison ER, Kim S-K, Welsh RM: Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005, 174: 614-618.
28. Fang M, Siciliano NA, Hersperger AR, Roscoe F, Hu A, Ma X, Shamsedeen AR, Eisenlohr LC, Sigal LJ: Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc Natl Acad Sci U S A 2012, 109: 9983-9988. doi:10.1073/pnas.1202143109/-/DCSupplemental 10.1073/pnas.1202143109
29. Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300: 339-342. doi:10.1126/science.1083317 10.1126/science.1083317
30. Xu R, Johnson AJ, Liggitt D, Bevan MJ: Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172: 6265-6271.
31. Bachmann MF, Wolint P, Schwarz K, Oxenius A: Recall proliferation potential of memory CD8+ T cells and antiviral protection. J Immunol 2005, 175: 4677-4685.
32. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao J-L, Murphy PM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005, 202: 1087-1098. doi:10.1084/jem.20042530 10.1084/jem.20042530
33. Glass WG, Liu MT, Kuziel WA, Lane TE: Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. Virology 2001, 288: 8-17. doi:10.1006/viro.2001.1050 10.1006/viro.2001.1050
34. Nansen A, Christensen JP, Andreasen SØ, Bartholdy C, Christensen JE, Thomsen AR: The role of CC chemokine receptor 5 in antiviral immunity. Blood 2002, 99: 1237-1245. 10.1182/blood. V99.4.1237
35. Christensen JE, Nansen A, Moos T, Lu B, Gerard C, Christensen JP, Thomsen AR: Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci 2004, 24: 4849-4858. doi:10.1523/JNEUROSCI.0123-04.2004 10.1523/JNEUROSCI.0123-04.2004
36. Engelhardt B, RansohoffRM: Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012, 33: 579-589. doi:10.1016/j.it.2012.07.004 10.1016/j.it.2012.07.004
37. Irani DN, Griffin DE: Regulation of lymphocyte homing into the brain during viral encephalitis at various stages of infection. J Immunol 1996, 156: 3850-3857.
38. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F: C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10: 514-523. doi:10.1038/ni.1716 10.1038/ni.1716
39. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24: 179-189. doi:10.1016/j.immuni.2006.01.001 10.1016/j.immuni.2006.01.001
40. Mangan PR, Harrington LE, O'quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441: 231-234. doi:10.1038/nature04754 10.1038/nature04754
41. Zhang N, Bevan MJ: Transforming growth factor-β signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. Immunity 2013, 39: 687-696. doi:10.1016/j.immuni.2013.08.019 10.1016/j.immuni.2013.08.019
42. Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnière L, Poirier J, Duquette P, Talbot PJ, Arbour N, Prat A: Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain 2011, 134: 3560-3577. doi:10.1093/brain/awr268 10.1093/brain/awr268
43. Oxenius A, Bachmann MF, Zinkernagel RM, Hengartner H: Virus-specific major MHC class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol 1998, 28: 390-400. 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O
44. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM, O'Shea JJ: Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26: 371-381. doi:10.1016/j.immuni.2007.02.009 10.1016/j.immuni.2007.02.009
45. Brown DM, Kamperschroer C, Dilzer AM, Roberts DM, Swain SL: IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 2009, 257: 69-79. doi:10.1016/j.cellimm.2009.03.002 10.1016/j.cellimm.2009.03.002
46. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A: Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010, 32: 79-90. doi:10.1016/j.immuni.2009.11.012 10.1016/j.immuni.2009.11.012
47. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, Swain SL: IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009, 182: 7353-7363. doi:10.4049/jimmunol.0900657 10.4049/jimmunol.0900657
48. Hou W, Kang HS, Kim BS: Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009, 206: 313-328. doi:10.1084/jem.20082030 10.1084/jem.20082030
49. Tate MD, Deng Y-M, Jones JE, Anderson GP, Brooks AG, Reading PC: Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 2009, 183: 7441-7450. doi:10.4049/jimmunol.0902497 10.4049/jimmunol.0902497
50. Barker BR, Gladstone MN, Gillard GO, Panas MW, Letvin NL: Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol 2010, 40: 3085-3096. doi:10.1002/eji.200939939 10.1002/eji.200939939
51. Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, He R, Leung DYM, Howell MD, Oettgen HC, Murphy GF, Geha RS: Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci U S A 2009, 106: 14954-14959. doi:10.1073/pnas.0904021106 10.1073/pnas.0904021106
52. Suryawanshi A, Veiga-Parga T, Rajasagi NK, Reddy PBJ, Sehrawat S, Sharma S, Rouse BT: Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J Immunol 2011, 187: 1919-1930. doi:10.4049/jimmunol.1100736 10.4049/jimmunol.1100736
53. Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R: Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011, 134: 2687-2702. doi:10.1093/brain/awr206 10.1093/brain/awr206